Apellis Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell APLS and other ETFs, options, and stocks.About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE.
CEOCedric Francois
CEOCedric Francois
Employees710
Employees710
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2009
Founded2009
Employees710
Employees710
APLS Key Statistics
Market cap3.03B
Market cap3.03B
Price-Earnings ratio83.77
Price-Earnings ratio83.77
Dividend yield—
Dividend yield—
Average volume1.90M
Average volume1.90M
High today—
High today—
Low today—
Low today—
Open price$24.78
Open price$24.78
Volume0.00
Volume0.00
52 Week high$35.57
52 Week high$35.57
52 Week low$16.10
52 Week low$16.10
Stock Snapshot
With a market cap of 3.03B, Apellis Pharmaceuticals(APLS) trades at $23.81. The stock has a price-to-earnings ratio of 83.77.
On 2026-01-07, Apellis Pharmaceuticals(APLS) stock opened at $24.78, reached a high of —, and a low of —.
Apellis Pharmaceuticals(APLS) shares are trading with a volume of 0, against a daily average of 1.9M.
In the last year, Apellis Pharmaceuticals(APLS) shares hit a 52-week high of $35.57 and a 52-week low of $16.10.
In the last year, Apellis Pharmaceuticals(APLS) shares hit a 52-week high of $35.57 and a 52-week low of $16.10.
Analyst ratings
62%
of 21 ratingsBuy
61.9%
Hold
33.3%
Sell
4.8%
People also own
Based on the portfolios of people who own APLS. This list is generated using Robinhood data, and it’s not a recommendation.